Animal Health Asia 2022

Animal Health, Nutrition and Technology Innovation Asia

Advancing Innovation, Product Regulation and Strategic Corporate Partnerships in Asia Pacific

View 2022 Agenda
Bangkok, Thailand
18-19 October, 2022

“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed! ”

Jishu Shi, U.S.-China Centre for Animal Health

Why Attend

Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.  

Across regions of Asia, prediction, prevention, and treatment of disease in animals are becoming increasingly important, with Japan and China continuing to lead the charge, but we are seeing new markets emerging including Thailand, India, Indonesia, Vietnam, Singapore, South Korea, and Malaysia. One of the biggest challenges in this region for large animal health companies is sourcing innovation, and for start-ups, it is entering new markets. 

Animal Health, Nutrition and Technology Innovation Asia 2022 tackle these challenges as well as provide a critical opportunity for face-to-face meetings.

200+
Attendees
21+
Private Meetings Per Person
7+
hours dedicated networking time
50+
Start-ups in attendance

Who You Will Meet

Attendees will represent the following key stakeholder groups in the Animal Health market

  • Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
  • CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
  • CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers

…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets

Attendees expected from the following key stakeholder groups and organizations

2022 Speakers

 

Abhilash Sethi

Principal
Omnivore

Abhilash Sethi

Principal
Omnivore

Abhilash Sethi

Principal
Omnivore
 

Mr. Katsutoshi Kato

Senior Vice President, International Operations
Zoetis Asia Cluster

Mr. Katsutoshi Kato

Senior Vice President, International Operations
Zoetis Asia Cluster

Mr. Katsutoshi Kato

Senior Vice President, International Operations
Zoetis Asia Cluster
 

Dr. Yuki Ujimasa

President
AHRMS, Inc

Dr. Yuki Ujimasa

President
AHRMS, Inc

Dr. Yuki Ujimasa

President
AHRMS, Inc
 

Mr. Vijay Teng

President
INTAS Pharma

Mr. Vijay Teng

President
INTAS Pharma

Mr. Vijay Teng

President
INTAS Pharma
 

Michael Boddington

Managing Director
AARTD - Asian Agribusiness Recruitment Training & Development

Michael Boddington

Managing Director
AARTD - Asian Agribusiness Recruitment Training & Development

Michael Boddington

Managing Director
AARTD - Asian Agribusiness Recruitment Training & Development
 

Miles Yao

Managing Director
AgConsulting

Miles Yao

Managing Director
AgConsulting

Miles Yao

Managing Director
AgConsulting
 

Mr. Tony Tan

Founder and Managing Partner
Z-Link Biotech

Mr. Tony Tan

Founder and Managing Partner
Z-Link Biotech

Mr. Tony Tan

Founder and Managing Partner
Z-Link Biotech
 

Dr. Griff Dalgleish

Director of Technical Affairs and Ruminant Business
MSD

Dr. Griff Dalgleish

Director of Technical Affairs and Ruminant Business
MSD

Dr. Griff Dalgleish

Director of Technical Affairs and Ruminant Business
MSD
 

Dr. Gandhi Sivakumar

Distinguished Engineer, Analytics, IBM Software
IBM Australia

Dr Magdoline Awad has a Bachelor of Veterinary Science degree from the University of Sydney, a graduate degree in Veterinary Professional Practice Management, and Membership of the Australian and New Zealand College of Veterinary Scientists in the Animal Welfare Chapter.

Dr. Gandhi Sivakumar

Distinguished Engineer, Analytics, IBM Software
IBM Australia

Dr. Gandhi Sivakumar

Distinguished Engineer, Analytics, IBM Software
IBM Australia

Dr Magdoline Awad has a Bachelor of Veterinary Science degree from the University of Sydney, a graduate degree in Veterinary Professional Practice Management, and Membership of the Australian and New Zealand College of Veterinary Scientists in the Animal Welfare Chapter.

She was appointed to the Veterinary Practitioners Board of NSW in 2019 representing vets in urban areas. She is a member of the UNSW Animal Care and Ethics Committee and the NSW representative for the AVA Welfare and Ethics special interest group. She was previously a member of the Animal Research and Review Panel NSW from 2008-2016. Mags was also a member of the Sydney School of Veterinary Science Admissions Committee for the DVM degree from 2014-2019.

Mags was Chief Veterinarian at RSPCA NSW from 2008-2015, after starting with the organisation in 1996. The Chief Veterinarian was responsible for the organisation’s 4 Veterinary hospitals. She was involved in the development and management of community programs in remote regional areas of NSW, working with local veterinarians and government to improve the welfare of pets in those communities. Programs for the disadvantaged, including the elderly have since been incorporated into the University of Sydney Veterinary Undergraduate Degree. The role also included Veterinary oversight of animal cruelty matters, ensuring adherence to legislation and policy and any related media.

Prior to her role at Greencross, Mags spent 4 years as the Chief Veterinary Officer for PetSure, working closely with the Veterinary Profession and Industry to increase Pet Insurance awareness and penetration in Australia.

 

Dr. Alfred Chua

Chief Marketing Officer
Biovalence Technologies

Dr. Alfred Chua

Chief Marketing Officer
Biovalence Technologies

Dr. Alfred Chua

Chief Marketing Officer
Biovalence Technologies
 

Giana Gomes

Head of Marine Biotechnology
Temasek Life Sciences Laboratory

Giana Gomes

Head of Marine Biotechnology
Temasek Life Sciences Laboratory

Giana Gomes

Head of Marine Biotechnology
Temasek Life Sciences Laboratory
 

Jon Sandbrook

Investment Manager
New Zealand Trade and Enterprise (NZTE)

Jon Sandbrook

Investment Manager
New Zealand Trade and Enterprise (NZTE)

Jon Sandbrook

Investment Manager
New Zealand Trade and Enterprise (NZTE)
 

Justin Sherrard

Global Strategist Animal Protein
Rabobank

Justin Sherrard

Global Strategist Animal Protein
Rabobank

Justin Sherrard

Global Strategist Animal Protein
Rabobank
 

Karolina Bate

Managing Director
Knoell

Karolina Bate

Managing Director
Knoell

Karolina Bate

Managing Director
Knoell
 

Masahiko Yamada

Co-Founder and Managing Director
Umitron

Masahiko Yamada

Co-Founder and Managing Director
Umitron

Masahiko Yamada

Co-Founder and Managing Director
Umitron
 

Nackanun Chitaroon

President
Animal Health Products Association

Nackanun Chitaroon

President
Animal Health Products Association

Nackanun Chitaroon

President
Animal Health Products Association
 

Prasad Vanga

CEO and Founder
Anthill Ventures

2008 - 2011: Division Director of International Business based at the Zenoaq Beijing Representative Office

2011- 2016: Company President of Nippon Biologicals, Inc. [Zenoaq affiliate]

2013 - 2016: Executive Director of International Business [Zenoaq]

2016: Company President of Vetoquinol Zenoaq K.K.

2016 - 2018: Executive Vice President of Zenoaq

2018 - present: Company President

 

Prasad Vanga

CEO and Founder
Anthill Ventures

Prasad Vanga

CEO and Founder
Anthill Ventures

2008 - 2011: Division Director of International Business based at the Zenoaq Beijing Representative Office

2011- 2016: Company President of Nippon Biologicals, Inc. [Zenoaq affiliate]

2013 - 2016: Executive Director of International Business [Zenoaq]

2016: Company President of Vetoquinol Zenoaq K.K.

2016 - 2018: Executive Vice President of Zenoaq

2018 - present: Company President

 

 

Pushpanathan Sundram

Executive Director
Asia Animal Health Association

Pushpanathan Sundram

Executive Director
Asia Animal Health Association

Pushpanathan Sundram

Executive Director
Asia Animal Health Association
 

Ritu Verma

Co-Founder, Managing Partner
Ankur Capital

Ritu Verma

Co-Founder, Managing Partner
Ankur Capital

Ritu Verma

Co-Founder, Managing Partner
Ankur Capital
 

Sunil Pande

Food Investor

Sunil Pande

Food Investor

Sunil Pande

Food Investor
 

Tony Chen

CEO
Manolin

Tony Chen

CEO
Manolin

Tony Chen

CEO
Manolin
 

Vick Chung

President
Vetnostrum

Vick Chung

President
Vetnostrum

Vick Chung

President
Vetnostrum
 

Dr. Zhao Yarong

Tianjin Ringpu

Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.

From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.

Dr. Zhao Yarong

Tianjin Ringpu

Dr. Zhao Yarong

Tianjin Ringpu

Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.

From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.

In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.

 

Mr. Yoshio Hase

Head of Business Administration and Practice Management
Elsa Kreis

Mr. Yoshio Hase

Head of Business Administration and Practice Management
Elsa Kreis

Mr. Yoshio Hase

Head of Business Administration and Practice Management
Elsa Kreis
 

Arkhom Cheewakriengkrai

Cheewakriengkrai Vice President: South Asia and Southeast Asia
Zoetis

Arkhom Cheewakriengkrai

Cheewakriengkrai Vice President: South Asia and Southeast Asia
Zoetis

Arkhom Cheewakriengkrai

Cheewakriengkrai Vice President: South Asia and Southeast Asia
Zoetis

Testimonials

"This is a unique event for our animal health industry. It brings local and international players together, and provides an excellent platform to build business partnerships.”

Tony Zilong Tan, Z-Link Biotech Co. Ltd.

 

“This meeting is a very exciting one – it’s a platform to meet everyone from Chinese animal health and International animal health companies, and to introduce them to one-another. This way you save time and it gives you more chance to keep ahead of the innovations.”

Tingwu Xue, China Animal Husbandry Group (CAHG)

 

“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed!"

Jishu Shi, U.S.-China Centre for Animal Health

 

"Everybody’s here, you can have many meetings in one spot, learn how to work together, increase your network and search for ideas.”
Joachim Hasenmaier, Boehringer-Ingelheim

Partners

Associate Partner

Senior Event Partner

Event Partner

Consulting Partner

Media Partners

Become a Partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]

Resources

Download Resource

2021 Agenda

Find out who is speaking in Bangkok in 2022

Simply fill out your details to view the full agenda.


Download the 2022 Agenda

Register

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket prices will increase in

Wednesday, May 11, 2022 to Friday, July 1, 2022
Emerging Companies
$799
Super Early Bird offer ends 1 July
Only 4 tickets remaining at this price point
Academics
Start-ups & Emerging
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Wednesday, May 11, 2022 to Friday, July 1, 2022
Delegates
$1799
Super Early Bird offer ends 1 July
Only 4 tickets remaining at this price point
Pharmaceutical Companies
Animal Health Companies
To increase your brand presence, contact Stephen: [email protected]
Wednesday, May 11, 2022 to Friday, July 1, 2022
Multinationals & Service Providers
$2,499
Super Early Bird offer ends 1 July
CROs & CMOs
Multinationals
Service Providers
Companies with over $100m annual turnover
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...

Global Advisory Board

WHO THEY ARE

Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.

WHY THEY ARE HERE

Board members guide not just content, but also the underlying mission of the events to drive positive change.

Author:

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Author:

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Aaron Schacht

President/ CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Chief Executive Officer
Virbac

Sébastien Huron

Chief Executive Officer
Virbac

Author:

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

Linda Rhodes

Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Linda Rhodes

Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Author:

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

ORGANISING COMMITTEE

This esteemed group is responsible for identifying and evaluating innovative emerging companies for
presentation as part of our Innovation Showcases. Each of our committee members has an extensive
breadth of experience and knowledge across animal health and nutrition industries and will be available
for meetings at the conference.

Author:

Mr. Nigel Nichols

Animal Health Consultant

Mr. Nigel Nichols

Animal Health Consultant

Author:

Mr. Vijay Teng

President
INTAS Pharma

Mr. Vijay Teng

President
INTAS Pharma

Author:

Mr. Tony Tan

Founder and Managing Partner
Z-Link Biotech

Mr. Tony Tan

Founder and Managing Partner
Z-Link Biotech

Author:

Mr. Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

 Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.

In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector. 

 

Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity. 

From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.

 

Contact:

[email protected]

Mr. Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

 Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.

In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector. 

 

Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity. 

From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.

 

Contact:

[email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us